首页> 外文期刊>Proceedings of the National Academy of Sciences of the United States of America >Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.
【24h】

Mechanism for nucleoside analog-mediated abrogation of HIV-1 replication: balance between RNase H activity and nucleotide excision.

机译:HIV-1复制的核苷类似物介导的消除机制:RNase H活性和核苷酸切除之间的平衡。

获取原文
获取原文并翻译 | 示例
       

摘要

Understanding the mechanisms of HIV-1 drug resistance is critical for developing more effective antiretroviral agents and therapies. Based on our previously described dynamic copy-choice mechanism for retroviral recombination and our observations that nucleoside reverse transcriptase inhibitors (NRTIs) increase the frequency of reverse transcriptase template switching, we propose that an equilibrium exists between (i) NRTI incorporation, NRTI excision, and resumption of DNA synthesis and (ii) degradation of the RNA template by RNase H activity, leading to dissociation of the template-primer and abrogation of HIV-1 replication. As predicted by this model, mutations in the RNase H domain that reduced the rate of RNA degradation conferred high-level resistance to 3'-azido-3'-deoxythymidine and 2,3-didehydro-2,3-dideoxythymidine by as much as 180- and 10-fold, respectively, by increasing the time available for excision of incorporated NRTIs from terminated primers. These results provide insights into the mechanism by which NRTIs inhibit HIV-1 replication and imply that mutations in RNase H could significantly contribute to drug resistance either alone or in combination with NRTI-resistance mutations in reverse transcriptase.
机译:了解HIV-1耐药性的机制对于开发更有效的抗逆转录病毒药物和疗法至关重要。基于我们先前描述的逆转录病毒重组的动态拷贝选择机制,以及我们的观察结果,即核苷逆转录酶抑制剂(NRTIs)会增加逆转录酶模板转换的频率,我们建议(i)NRTI掺入,NRTI切除和恢复DNA合成和(ii)通过RNase H活性降解RNA模板,从而导致模板引物解离和废除HIV-1复制。如该模型所预测的,降低RNA降解速率的RNase H结构域突变赋予对3'-叠氮基3'-脱氧胸苷和2,3-didehydro-2,3-dideoxythymidine的高水平抗性通过增加可用于从终止引物中切除掺入的NRTI的时间分别增加180倍和10倍。这些结果提供了对NRTIs抑制HIV-1复制的机制的深刻见解,并暗示RNase H中的突变可单独或与逆转录酶的NRTI抗性突变组合显着促进耐药性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号